A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Melanoma
Interventions
DRUG

ipilimumab (MDX-010, BMS-734016)

IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.

Trial Locations (53)

Unknown

Little Rock

San Francisco

Santa Monica

Chicago

Park Ridge

Goshen

Hazard

Albuquerque

New York

Portland

Greenville

Knoxville

Dallas

Charlottesvillle

Local Institution, Salzburg

Local Institution, Vienna

Local Institution, Wels

Local Institution, Turku

Local Institution, Genova

Local Institution, Meldola

Local Institution, Milan

Local Institution, Napoli

Local Institution, Padua

Local Institution, Siena

Local Institution, Torino

Local Institution, Oslo

Local Institution, Lodz

Local Institution, Poznan

Local Institution, Wroclaw

Local Institution, Barnaul

Local Institution, Moscow

Local Institution, Murmansk

Local Institution, Ryazan

Local Institution, Saint Petersburg

Local Institution, Samara

Local Institution, Stavropol

Local Institution, Veliky Novgorod

Local Institution, Voronezh

Local Institution, Barcelona

Local Institution, Madrid

Local Institution, Málaga

Local Institution, Santa Cruz de Tenerife

Local Institution, Valencia

Local Institution, Gothenburg

Local Institution, Lund

Local Institution, Stockholm

Local Institution, Uppsala

Local Institution, Cherkassy

Local Institution, Dnipropetrovsk

Local Institution, Kiev

Local Institution, Lviv

Local Institution, Sumy

Local Institution, Uzhhorod

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medarex

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY